NovoCure Ltd (NAS:NVCR)

$ 23.15 0.84 (3.77%) Market Cap: 2.49 Bil Enterprise Value: 2.22 Bil PE Ratio: 0 PB Ratio: 6.93 GF Score: 60/100

Q1 2024 Novocure Ltd Earnings Call Transcript
May 02, 2024

$14.19 (+11.38%)

Earnings
Q4 2023 Novocure Ltd Earnings Call Transcript
Feb 22, 2024

$15.24 (-2.43%)

Earnings
Novocure Ltd at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Novocure Ltd at Piper Sandler Healthcare Conference Transcript
Nov 29, 2023
Q3 2023 Novocure Ltd Earnings Call Transcript
Oct 26, 2023

$13.02 (-7.53%)

Earnings
Novocure Ltd at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Novocure Ltd at Wells Fargo Healthcare Conference Transcript
Sep 07, 2023
Q2 2023 Novocure Ltd Earnings Call Transcript
Jul 27, 2023

$33.93 (-15.89%)

Earnings
Novocure Ltd LUNAR Phase 3 Clinical Trial Presentation Transcript
Jun 06, 2023
Q1 2023 Novocure Ltd Earnings Call Transcript
May 04, 2023

$66.74 (+1.21%)

Earnings
Q4 2022 Novocure Ltd Earnings Call Transcript
Feb 23, 2023

$78.29 (-4.54%)

Earnings
Novocure Ltd at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Novocure Ltd at Piper Sandler Healthcare Conference Transcript
Dec 01, 2022
Q3 2022 Novocure Ltd Earnings Call Transcript
Oct 27, 2022

$67.87 (+0.24%)

Earnings
Novocure Ltd at Wells Fargo Healthcare Conference Transcript
Sep 07, 2022
Q2 2022 Novocure Ltd Earnings Call Transcript
Jul 28, 2022

$70.24 (-5.03%)

Earnings
Q1 2022 Novocure Ltd Earnings Call Transcript
Apr 28, 2022

$77.18 (+0.30%)

Earnings
Q4 2021 Novocure Ltd Earnings Call Transcript
Feb 24, 2022

$77.89 (+6.76%)

Earnings
Novocure Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Novocure Ltd at Piper Sandler Healthcare Conference (Virtual) Transcript
Nov 30, 2021
Q3 2021 Novocure Ltd Earnings Call Transcript
Oct 28, 2021

$101.74 (-8.16%)

Earnings
Novocure Ltd at Wells Fargo Virtual Healthcare Conference Transcript
Sep 10, 2021
Q2 2021 Novocure Ltd Earnings Call Transcript
Jul 29, 2021

$164 (-9.85%)

Earnings
Q1 2021 Novocure Ltd Earnings Call Transcript
Apr 29, 2021

$205.31 (-0.09%)

Earnings
Q4 2020 Novocure Ltd Earnings Call Transcript
Feb 25, 2021

$148.9 (-14.00%)

Earnings
Novocure Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021
Novocure Ltd at Evercore ISI HealthCONx Conference (Virtual) - Fireside Chat Transcript
Dec 02, 2020
Novocure Ltd Virtual Research & Development Day Transcript
Nov 12, 2020
Q3 2020 Novocure Ltd Earnings Call Transcript
Oct 29, 2020

$123.27 (+6.83%)

Earnings
Novocure Ltd at Wells Fargo Virtual Healthcare Conference Transcript
Sep 09, 2020
Q2 2020 Novocure Ltd Earnings Call Transcript
Jul 30, 2020

$76.17 (+12.01%)

Earnings
Q1 2020 Novocure Ltd Earnings Call Transcript
Apr 30, 2020

$65.8 (-10.52%)

Earnings
Q4 2019 Novocure Ltd Earnings Call Transcript
Feb 27, 2020

$77.28 (-2.73%)

Earnings
Novocure Ltd at JPMorgan Healthcare Conference Transcript
Jan 13, 2020
Q3 2019 Novocure Ltd Earnings Call Transcript
Oct 31, 2019

$71.64 (-3.54%)

Earnings
Q2 2019 Novocure Ltd Earnings Call Transcript
Jul 25, 2019

$77.08 (+8.58%)

Earnings
Q1 2019 Novocure Ltd Earnings Call Transcript
May 02, 2019

$44.6 (+3.05%)

Earnings
Q4 2018 Novocure Ltd Earnings Call Transcript
Feb 28, 2019

$53.71 (-0.50%)

Earnings

Novocure Ltd at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 03:30PM GMT

Release Date Price: $93.03 (+1.95%)

Transcript 8-K

Jessica Macomber Fye

JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan. Welcome back for Day 2 of our very in-person health care conference. A little different format this year than in the past. You're not going to switch rooms for Q&A. So we're going to, after the presentation, just go seamlessly into Q&A. There's 2 ways to ask questions. You can raise your hand and some will bring you a mic. You can also submit questions electronically through our portal. We'll send it to that iPad up there, and I can read them off for the management team.

So with that out of the way, let me pass it over to NovoCure's Executive Chairman, Bill Doyle for the presentation.

William F. Doyle

NovoCure Limited - Executive Chairman

Thank you, Jess. Good morning, everyone. Welcome to the Sunrise session at JPMorgan. I wasn't sure whether they'd actually be anybody in the room or not at 7:30. So I'm pleased to see everyone. I'll be making forward-looking statements.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.